Compare Expedia Group Inc (EXPE) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs McKesson Corporation — how do they compare? Expedia Group Inc trades at $274 (market cap $32.42B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 3.3× Expedia Group Inc's market cap, and Expedia Group Inc pays the higher dividend (0.71%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and McKesson Corporation for 74 Days on average.
| EXPE | MCK | |
|---|---|---|
Market Cap | $32.42B | $108.46B |
Volume | 1,940,671 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $995.69 |
52-Week Low | $188.51 | $725.17 |
Typical Hold Time | 47 Days | 74 Days |
Enterprise Value | $30.98B | $115.00B |
Dividend Yield | 0.71% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.22, up 5.93% over the past 24 hours, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows a bullish technical signal with key resistance at $275 and support at $264. Fundamentally, the company reported $14.73B in 2025 revenue with a net income margin of 12.97%, while recent news highlights AI-driven competitive pressures and strategic partnerships.
The outlook for EXPE is cautiously optimistic, with a consensus price target of $335.06 implying 22% upside. Key opportunities include robust travel demand and improving profitability, but risks involve AI disruption from Meta's Muse agent and heightened competition. Analyst sentiment is mixed, with 47% buy ratings versus 50% hold, signaling balanced but uncertain near-term prospects.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
